Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study).
about
Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysisSurgical revascularisation in patients with severe limb ischaemia induces a pro-thrombotic stateLow-molecular-weight heparins: pharmacoeconomic decision modeling based on meta-analysis data.Impact of red blood cell transfusion on platelet activation and aggregation in healthy volunteers: results of the TRANSFUSION study.Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndrome.Bleeding risk during treatment of acute thrombotic events with subcutaneous LMWH compared to intravenous unfractionated heparin; a systematic review.The Interface between Inflammation and Coagulation in Cardiovascular Disease.Biosimilars of low-molecular-weight heparin products: fostering competition or reducing 'biodiversity'?Low-molecular-weight heparin vs. unfractionated heparin in percutaneous coronary intervention: a combined analysis.Effect of Heparin Administration during Coronary Angiography on Vascular or Peripheral Complications: A Single-Blind Randomized Controlled Clinical Trial.Platelet function testing and implications for clinical practice.Platelet biology and implications for antiplatelet therapy in atherothrombotic disease.US Food and Drug Administration approval of generic versions of complex biologics: implications for the practicing physician using low molecular weight heparins.Low molecular weight heparin biosimilars: how much similarity for how much clinical benefit?Anti-Inflammatory Effects of Heparin and Its Derivatives: A Systematic ReviewThe Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy.Comparison of the Effects of Enoxaparin and Heparin on Inflammatory Biomarkers in Patients with ST-segment Elevated Myocardial Infarction: A prospective Open Label Pilot Clinical Trial.Role of enoxaparin resistance in recurrent chest pain in the intensive care unit.Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: An ENTIRE-TIMI 23 substudy.Influence of prolonged dalteparin treatment on coagulation, fibrinolysis and inflammation in unstable coronary artery disease.Low-molecular-weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis.The Efficacy and Safety of Enoxaparin: A Meta-analysis
P2860
Q26853150-05ADAC4B-DD7F-4D06-A0B6-1036616EBD65Q28200258-5956816B-C69C-43F1-96D0-0579710C5D79Q33618610-26ACBB8F-E88E-461A-8052-56B45BA607FFQ33622182-1A74F4CC-A9CD-429A-8490-8B3AF3F6B22FQ33750461-8F454ED6-7F01-4BE6-9D52-8396ED77735BQ34415964-403A83E9-BCE9-4AE5-9CF1-640C06B54E7DQ35821321-E4A6659C-6E71-4AC3-B093-B660BCBCE8C1Q35880101-98EC929A-9678-438C-B0A9-D3784BFDC92AQ36131116-69E7249E-A762-4E0E-AE43-A19D421A4E58Q37338868-99EF2DD9-90F4-4F82-BA6E-55759F7AD226Q37590046-04088A5E-AF8F-474E-BD36-E48D89B40410Q37766688-A5BBA494-606B-4575-BAAB-8975B1185887Q37974873-9F0EDDE0-18D0-4422-8261-7F5D736CFB0EQ37978525-D9EA2852-B3AC-4DEC-8687-215F2ACDD527Q38524632-850AD7F5-FAE8-47F9-985D-614B627D8193Q38716432-95137464-DE74-46F9-838A-DDB6DD81C381Q42867694-4A7F96F7-34C5-4BDE-8AAD-259FC6728047Q43237435-319548A5-0514-4DBD-ACF7-9BEE623AD34CQ44517148-783F6FBF-D466-4626-B0F4-CDB9E067F1CDQ46765265-9EDC466A-2318-418D-AE99-76FE752D10EEQ47365108-1A201650-1B81-4B88-85C6-86AE3337D81AQ58757769-32D3C00A-3CBD-46B0-BE99-B60BF598E16F
P2860
Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study).
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Comparison of effects on marke ...... infarction (the ARMADA study).
@en
Comparison of effects on marke ...... infarction (the ARMADA study).
@nl
type
label
Comparison of effects on marke ...... infarction (the ARMADA study).
@en
Comparison of effects on marke ...... infarction (the ARMADA study).
@nl
prefLabel
Comparison of effects on marke ...... infarction (the ARMADA study).
@en
Comparison of effects on marke ...... infarction (the ARMADA study).
@nl
P2093
P50
P1476
Comparison of effects on marke ...... infarction (the ARMADA study).
@en
P2093
ARMADA Investigators
Ariel Cohen
Claire Bal-dit-Sollier
Daniela Chibedi
François Tarragano
Jean L Guermonprez
Jean-Philippe Collet
Jean-Philippe Metzger
Ludovic Drouet
Michel Slama
P304
P356
10.1016/S0002-9149(03)00105-X
P407
P577
2003-04-01T00:00:00Z